UPDATE: Morgan Stanley Reiterates Equal-Weight Rating, Removes PT on AbbVie on Potential of ABT-199

In a report published Thursday, Morgan Stanley analyst David Risinger reiterated an Equal-Weight rating on

, but removed the $47.00 price target. In the report, Morgan Stanley noted, “ABT-199 is a potential blockbuster blood cancer treatment that ABBV and Roche could launch in '16. In the U.S., ABBV and Roche will share profits/losses equally. Ex-U.S., ABBV will book sales and pay Roche a royalty (undisclosed). We highlight upcoming events below.” AbbVie closed on Wednesday at $50.63.